Beginning in mid-2026, Medicare will pay $149 to $245 per month for GLP-1 receptor agonist obesity drugs semaglutide (Wegovy—Novo Nordisk) and tirzepatide (Zepbound—Eli Lilly), depending on dosage.
APhA staff
Buoyed by increased usage among women and older adults, gabapentin—an anticonvulsant indicated for seizures but widely used off-label—has grown exponentially popular in the United States in recent years.
According to results of a large, retrospective cohort study in JAMA Network Open, regular screening for diabetic retinopathy is recommended for all patients with T2D receiving GLP-1 receptor agonists.
Researchers reported an association with increased health care costs when the Veterans Health Administration (VHA) formulary transitioned from budesonide-formoterol metered-dose inhalers to uticasone-salmeterol dry-powder inhalers.
An analysis published June 24, 2025, in The Lancet suggests the Immunization Agenda 2030—the WHO’s campaign to bolster global childhood vaccination rates—will not achieve its goals in the next 5 years.